MariMed Q1 2026 Earnings: $39.5M Revenue and the 'Expand the Brand' Playbook

MariMed Inc. (OTC: MRMD) dropped its first-quarter 2026 earnings on May 13, and while the multi-state operator isn't grabbing the same headlines as the Tier 1 MSOs racing to file DEA registrations, the numbers tell a quiet growth story that cannabis investors shouldn't ignore.

Revenue came in at $39.5 million for the quarter, up from $37.9 million in Q1 2025 — a 4.2 percent year-over-year increase driven by steady expansion across both retail storefronts and wholesale distribution channels. In a cannabis market where plenty of operators are reporting flat or declining top lines, any organic growth is worth paying attention to.

The Numbers at a Glance

The headline metric that management wants you to focus on is adjusted EBITDA. Non-GAAP adjusted EBITDA climbed to $3.6 million with a 9.1 percent margin, representing a 44 percent improvement over the same period last year. That's a meaningful step for a company that has been working to prove it can operate profitably without relying on one-time gains or accounting adjustments.

GAAP net loss narrowed to $3.8 million from $5.5 million in Q1 2025. The non-GAAP net loss was $3.2 million, and earnings per share landed at negative one cent — right on analyst consensus. Gross margin held steady at 38.7 percent on a GAAP basis and 40.1 percent when you strip out certain non-cash items.

Revenue breaks down into three buckets: retail product sales at $21.7 million, wholesale product sales at $17.5 million, and a small $0.2 million contribution from other revenue streams. The wholesale segment in particular showed improvement, reflecting the company's deliberate push to get its house brands onto dispensary shelves in markets where it doesn't operate its own stores.

The 'Expand the Brand' Strategy Explained

CEO Jon Levine described Q1 as a continuation of MariMed's "Expand the Brand" strategy — a phrase the company has been using for several quarters now to describe its approach to growth. Rather than pursuing the land-grab acquisition model that defined the cannabis MSO playbook from 2019 to 2022, MariMed is focused on taking its top-selling in-house brands and making them available to more consumers across existing and new markets.

This means investing in wholesale partnerships, building brand recognition at the dispensary level, and ensuring that product quality remains consistent as distribution expands. It's a lower-capital approach than buying entire operations, and it sidesteps some of the integration headaches that have tripped up larger MSOs.

The brands driving this effort include Betty's Eddies, a fruit-chew edible line that has built a loyal following in the Northeast, and Peanut Butter Breath pre-rolls, among other products. MariMed has been methodical about which markets it enters and which retail partners it works with, preferring to build deep relationships rather than blanket an entire state with product.

Capital Structure: Breathing Room on the Balance Sheet

One of the more significant developments this quarter was the March restructuring of $14.725 million in Series B convertible preferred stock. Previously, MariMed faced a mandatory conversion date in late February 2026 that would have forced a significant dilution event. Through a Restructuring and Exchange Agreement with preferred holders, the company replaced the near-term conversion obligation with longer-dated instruments, pushing the weighted average maturity out to 4.6 years.

This move eliminates an overhang that had been worrying investors and gives management more flexibility to execute its growth plan without the pressure of an imminent capital event. It also improves the company's liquidity profile at a time when cannabis operators across the board are finding traditional financing channels still largely closed.

Where MariMed Sits in the MSO Landscape

MariMed operates in a tier below the mega-MSOs like Curaleaf, Green Thumb Industries, and Trulieve, but that positioning may actually be an advantage in the current market environment. Smaller operators with disciplined capital allocation and strong unit economics have been outperforming their larger peers in terms of margin improvement, and MariMed's Q1 results fit that pattern.

The company currently holds licenses in Massachusetts, Illinois, Maryland, Missouri, Ohio, and Delaware — all states with either established adult-use markets or recently launched programs that are still ramping. Massachusetts and Illinois represent the core revenue engines, while Missouri and Maryland offer the most upside as those markets mature.

In a quarter where Organigram reported a nine percent revenue decline and Glass House saw its average selling price drop to $171 per pound, MariMed's modest but consistent growth stands out. The company isn't setting the world on fire, but it's doing something that few cannabis companies manage: growing the top line while simultaneously improving profitability metrics.

The Schedule III Angle

MariMed didn't announce any DEA registration filings during the quarter, but the Schedule III reclassification of medical cannabis creates a significant potential tailwind for the company. The elimination of the Section 280E tax burden alone could add meaningful dollars to the bottom line, since cannabis operators have historically been unable to deduct ordinary business expenses on their federal tax returns.

For a company like MariMed that is already approaching breakeven on an adjusted basis, 280E relief could be the difference between consistent profitability and continued losses. Management has been careful not to count those savings before they materialize, but investors are clearly factoring the possibility into their models.

What to Watch Going Forward

The next few quarters will be critical for validating the Expand the Brand thesis. Wholesale revenue growth will be the key metric — if MariMed can continue pushing its brands into new retail locations without sacrificing margin, the strategy is working. If wholesale growth stalls or gross margins compress, it may signal that the company is running into the same competitive pricing pressures that have squeezed other operators.

The preferred stock restructuring buys time, but MariMed will eventually need to demonstrate that it can generate consistent positive free cash flow. The adjusted EBITDA trend is encouraging, but EBITDA doesn't pay the bills — cash flow does.

For cannabis investors looking beyond the Tier 1 names, MariMed represents an interesting case study in disciplined, brand-focused growth. The Q1 numbers won't make anyone rich overnight, but they suggest a company that's executing a coherent plan in an industry where coherent plans are surprisingly rare.

MariMed held its earnings conference call on Thursday, May 14, at 8:00 a.m. Eastern. The full earnings release and financial statements are available on the company's investor relations page.

Looking for trustworthy cannabis options near you? Browse verified cannabis dispensaries on Budpedia — every listing is checked against state license rolls before going live, with live menus, deals, and reviews to help you decide where to shop.